Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
20 studies found for:    thrombocytopenia | Open Studies | NIH, U.S. Fed
Show Display Options
RSS Create an RSS feed from your search for:
thrombocytopenia | Open Studies | NIH, U.S. Fed
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Mathematical Modeling to Predict the Duration of Thrombocytopenia in Neonates
Condition: Neonatal Thrombocytopenia
Intervention:
2 Unknown  Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Conditions: Thrombocytopenia;   Hepatitis C;   HIV Infections
Intervention: Drug: Anti-D
3 Recruiting Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Conditions: Thrombocytopenia;   Alloimmune Platelet Refractoriness
Intervention: Drug: Eculizumab
4 Recruiting American Trial Using Tranexamic Acid in Thrombocytopenia
Condition: Thrombocytopenia
Interventions: Drug: Tranexamic Acid;   Drug: Placebo
5 Recruiting A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Conditions: Myelodysplastic Syndromes;   Thrombocytopenia
Intervention: Drug: Eltrombopag
6 Recruiting Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
Conditions: Aplastic Anemia;   Neutropenia;   Pancytopenia;   Anemia;   Thrombocytopenia
Interventions: Drug: Eltrombopag;   Drug: Horse Anti-Thymocyte Globulin (ATG);   Drug: Cyclosporine A (CSA)
7 Recruiting Screening for Hematology Branch Protocols
Conditions: Anemia;   Hematologic Neoplasm;   Neutropenia;   Pancytopenia;   Thrombocytopenia
Intervention:
8 Not yet recruiting Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis;   Polycythemia Vera;   Primary Myelofibrosis;   Thrombocytopenia
Interventions: Procedure: Bone Marrow Aspiration and Biopsy;   Other: Laboratory Biomarker Analysis;   Biological: Siltuximab
9 Recruiting Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
Condition: Glioma
Interventions: Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Etoposide Phosphate;   Other: Quality-of-Life Assessment;   Drug: Sodium Thiosulfate
10 Recruiting Extended Dosing With Eltrombopag for Severe Aplastic Anemia
Condition: Severe Aplastic Anemia (SAA)
Intervention: Drug: Eltrombopag
11 Recruiting Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation
Condition: Liver Transplantation
Interventions: Biological: Anti-Thymocyte Globulin - Rabbit;   Biological: darTreg Infusion;   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Prednisone;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Drug: Anti-Infective Prophylaxis;   Procedure: Leukapheresis;   Procedure: Blood draws;   Procedure: Liver biopsies;   Procedure: Liver transplantation
12 Recruiting Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990
Condition: Wiskott-Aldrich Syndrome
Intervention:
13 Recruiting Cancer in Inherited Bone Marrow Failure Syndromes
Conditions: Aplastic Anemia;   Head and Neck Neoplasms;   Bone Marrow Failure
Intervention:
14 Recruiting Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Neutrophilic Leukemia
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Drug: Ruxolitinib Phosphate
15 Recruiting Rituximab and Belimumab for Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Belimumab
16 Recruiting Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Interventions: Drug: Pentostatin;   Drug: Rituximab;   Drug: Bendamustine
17 Recruiting Pathogenesis of Physical Induced Urticarial Syndromes
Conditions: Autoinflammatory Syndromes;   Physical Urticaria
Intervention:
18 Recruiting Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: sorafenib tosylate;   Radiation: stereotactic body radiation therapy
19 Recruiting Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Conditions: Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Hodgkin Disease
Interventions: Biological: Antigen-Escalation Stage;   Biological: Dose-Escalation Stage;   Biological: 5-azacytidine and multiTAA T cells Stage;   Biological: Pediatric multiTAA T cells Stage
20 Recruiting Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura
Condition: Thrombotic Thrombocytopenic Purpura
Intervention: Biological: rituximab

Indicates status has not been verified in more than two years